The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models
Open Access
- 18 October 2002
- journal article
- fj express-summaries
- Published by Wiley in The FASEB Journal
- Vol. 16 (14) , 1991-1993
- https://doi.org/10.1096/fj.02-0509fje
Abstract
The de novo designed angiogenesis inhibitor anginex was tested in vitro and in vivo for its mechanism of action and antitumor activity. The data presented here demonstrate that anginex is a powerful ...Keywords
Funding Information
- National Institutes of Health (CA-96090)
This publication has 27 references indexed in Scilit:
- Distinct Antitumor Properties of a Type IV Collagen Domain Derived from Basement MembraneJournal of Biological Chemistry, 2000
- Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor GrowthThe Journal of Experimental Medicine, 1998
- Rocking the foundations of solid tumor growth by attacking the tumor's blood supplyImmunology Today, 1998
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- Definition of Two Angiogenic Pathways by Distinct α v IntegrinsScience, 1995
- A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4.Proceedings of the National Academy of Sciences, 1995
- The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation.The Journal of Experimental Medicine, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.Proceedings of the National Academy of Sciences, 1990